Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279001 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of Jaktinib
A Phase 1 study of Myelofibrosis, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT05279001: Recruiting Phase 1 study of Myelofibrosis, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
NCT05279001 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Suzhou Zelgen Biopharmaceuticals Co.. The registered enrollment target is 26 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05279001, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
Conditions Studied
Interventions
- DRUG Jaktinib Hydrochloride Tablet
Study Locations (1)
Ohio
- Site 01 - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 1 |
What NCT05279001 shows while recruiting
NCT05279001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Jaktinib Hydrochloride Tablet is the first listed.
NCT05279001 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05279001 about?
NCT05279001 is a clinical study titled "A Safety and Tolerability Study of Jaktinib". This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
What is the current status of trial NCT05279001?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-07-01. Estimated completion is 2025-11-30.
What conditions does trial NCT05279001 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT05279001?
The interventions under investigation include: Jaktinib Hydrochloride Tablet (DRUG).
Who is sponsoring clinical trial NCT05279001?
This trial is sponsored by Suzhou Zelgen Biopharmaceuticals Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279001 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05279001's enrollment target sits among peer trials
26 45th of 61 higher than 17 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI